RGC · Regencell Bioscience Holdings L
$5.72
+2.40% last session
End-of-day data · updated 2026-07-28
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
—
Dividend yield
—
Beta
1.83
Avg volume
0M
Employees
0K
2D change
—
5D change
3.74%
10D change
16.14%
30D change
-10.03%
60D change
-75.61%
MTD change
-27.40%
YTD change
-72.24%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Signal Summary as of 2026-07-28
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 57.4% below the 50-day MA ($14.02).
- Price vs 200-day MA: Trading 72.0% below the 200-day MA ($21.30).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.68) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($4.78) and high ($52.88).
RGC Price Chart
Loading chart for RGC…
Fundamentals
About Regencell Bioscience Holdings L
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.